An internal standard for the quantification of docosahexaenoyl ethanolamide
货号:ajcx22340
CAS:946524-43-2
分子式:C24H33D4NO2
分子量：375.6
溶解度:DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 0.15 mg/ml
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Docosahexaenoyl ethanolamide-d₄contains four deuterium atoms at the 1, 1', 2, and 2' positions. It is intended for use as an internal standard for the quantification of docosahexaenoyl ethanolamide by GC-or LC-mass spectrometry (MS). Docosahexaenoic Acid (DHA) is an essential fatty acid and the most abundant ω-3 fatty acid in neural tissues, especially in the retina and brain. Docosahexaenoyl ethanolamide (DHEA) is the ethanolamine amide of DHA that has been detected in both brain and retina at concentrations similar to those for arachidonoyl ethanolamide (AEA).^1,2A 9.5 fold increase of DHEA was observed in brain lipid extracts from piglets fed a diet supplemented with DHA compared to a control diet without DHA.³DHEA binds to the rat brain CB₁receptor with a K_ivalue of 324 nM, which is approximately 10-fold higher than the K_ivalue for AEA.⁴DHEA inhibits shaker-related voltage-gated potassium channels in brain slightly better than AEA, with an IC₅₀value of 1.5 µM.⁵

1.Sugiura, T., Kondo, S., Sukagawa, A., et al.Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamineEuropean Journal of Biochemistry24053-62(1996) 2.Bisogno, T., Delton-Vandenbroucke, I., Milone, A., et al.Biosynthesis and inactivation of N-Arachidonoylethanolamine (Ananadamide) and N-Docosahexaenoylethanolamine in bovine retinaArchives of Biochemistry and Biophysics370(2)300-307(1999) 3.Berger, A., Crozier, G., Bisogno, T., et al.Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in pigletsProceedings of the National Academy of Sciences of the United States of America98(11)6402-6406(2001) 4.Sheskin, T., Hanus, L., Slager, J., et al.Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptorJournal of Medicinal Chemistry40659-667(1997) 5.Poling, J.S., Rogawski, M.A., Salem, N., Jr., et al.Anadamide, an endogenous cannabinoid, inhibits shaker-related voltage-gated K+ channelsNeuropharmacology35(7)983-991(1996)